Mizuho restated their neutral rating on shares of Mednax, Inc (NYSE:MD) in a report issued on Tuesday, August 1st. They currently have a $48.00 target price on the stock, down from their prior target price of $62.00.
A number of other analysts have also commented on MD. Stifel Nicolaus cut their price target on Mednax from $65.00 to $58.00 and set a hold rating on the stock in a report on Thursday, May 25th. Jefferies Group LLC set a $46.00 target price on Mednax and gave the company a hold rating in a research report on Sunday, July 30th. BidaskClub raised Mednax from a strong sell rating to a sell rating in a research report on Tuesday, June 13th. TheStreet cut Mednax from a b- rating to a c+ rating in a research note on Tuesday, May 16th. Finally, ValuEngine cut Mednax from a buy rating to a hold rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. The company presently has an average rating of Hold and an average price target of $63.00.
Mednax (MD) opened at 42.27 on Tuesday. Mednax has a 52-week low of $41.52 and a 52-week high of $72.13. The company’s 50-day moving average price is $51.66 and its 200 day moving average price is $60.50. The firm has a market capitalization of $3.90 billion, a price-to-earnings ratio of 13.46 and a beta of 0.40.
In related news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $55.00, for a total transaction of $1,282,985.00. Following the transaction, the insider now owns 296,379 shares in the company, valued at $16,300,845. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the sale, the director now directly owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. boosted its position in shares of Mednax by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after buying an additional 145 shares during the last quarter. Ledyard National Bank raised its stake in shares of Mednax by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock worth $120,000 after buying an additional 275 shares during the last quarter. Commonwealth Bank of Australia raised its stake in shares of Mednax by 15.3% in the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after buying an additional 293 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock valued at $139,000 after buying an additional 1,794 shares in the last quarter. Finally, Morgan Dempsey Capital Management LLC raised its stake in Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares in the last quarter.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
What are top analysts saying about Mednax Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mednax Inc and related companies.